Sort   by:  
 Page size 
UnknownFactors associated with adverse haemodynamic events during the STARRT-AKI trial: a post-hoc secondary analysis.
Not available
S-EPMC12751851 | biostudies-literature
UnknownCommon, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity.
Not available
S-EPMC8661833 | biostudies-literature
UnknownEffects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial.
Not available
S-EPMC7645733 | biostudies-literature
UnknownCost-Utility Analysis of Accelerated and Standard Strategies for Renal Replacement Therapy Initiation.
Not available
S-EPMC12495491 | biostudies-literature
UnknownA Bayesian reanalysis of the Standard versus Accelerated Initiation of Renal-Replacement Therapy in Acute Kidney Injury (STARRT-AKI) trial.
Not available
S-EPMC9404618 | biostudies-literature
UnknownRegional Practice Variation and Outcomes in the Standard Versus Accelerated Initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI) Trial: A Post Hoc Secondary Analysis.
Not available
S-EPMC10878545 | biostudies-literature
UnknownEmpagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC10957483 | biostudies-literature
UnknownAspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC8598213 | biostudies-literature
UnknownBaricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
Not available
S-EPMC9333998 | biostudies-literature
UnknownCasirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC8830904 | biostudies-literature
Sort   by:  
 Page size